Market Cap
$6.8B
ALKS
Alkermes plc.
$41.64 ▲ +2.71%
Prev close $40.54Market cap$6.8B
ConsensusBuy
12-mo target$56.56 (+35.8%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on ALKS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (76%)
Inst. Holders
1 funds
Inst. Value
$17.00
Insider Activity
$0.00 buy / $5.5M sell
Insider Net $
-$5.5M
SEC Reports
18
Price chart 30d -12.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 short_volume
Sep 16, 2026 SEC Short Volume: ALKS — 55.6% short (0.5M / 0.9M)
Short: 500,068 | Exempt: 0 | TRF Vol: 899,125 | Short Ratio: 55.6% | Off-exchange volume (dark pool
Alkermes appointed Anne C. Whitaker as an independent director, expanding the board from 10 to 11 members. Ms. Whitaker
8-K — Impact 2/10
Two senior Alkermes executives (EVP/CLO and EVP R&D/CMO) sold a combined $521K in open-market shares over a 3-day window
CLUSTER — Impact 2/10
Sep 3, 2026 Insider
Gaffin David Joseph sold 2,034 shares
EVP, CLO, Alkermes, Inc. @ $48.01 ($97.7K)
Sep 1, 2026 Insider
Hopkinson Craig C. acquired via exercise 5,000 shares
EVP R&D, Chief Medical Officer @ $24.59 ($123.0K)
Sep 1, 2026 Insider
Aug 8, 2026 SEC Hopkinson Craig C. sold 9,000 shares
EVP R&D, Chief Medical Officer @ $46.99 ($422.9K)
Three Alkermes insiders, including a director and two EVPs, sold a total of $2.78M in open-market shares on August 3, 20
CLUSTER — Impact 4/10
Analyst ratings buy % -8.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
76% rate it Buy or better · 25 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | RBC Capital | REITERATE | Outperform | 55% |
| Sep 22, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Sep 21, 2026 | Needham | REITERATE | Buy | 50% |
| Jul 29, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Jul 29, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jul 28, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Jul 20, 2026 | Stifel | REITERATE | Buy | 54% |
| Jul 13, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 2, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jun 29, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 13 | 5 | 1 | 0 | 76% | |
| Aug 1, 2026 | 6 | 13 | 5 | 1 | 0 | 76% | |
| Jul 1, 2026 | 6 | 13 | 3 | 1 | 0 | 83% | |
| Jun 1, 2026 | 6 | 13 | 4 | 0 | 0 | 83% | |
| May 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Apr 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Mar 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Feb 1, 2026 | 5 | 14 | 4 | 0 | 0 | 83% |
Price targets
Where 18 covering analysts think ALKS trades over the next 12 months.
$56.56 +35.8% upside Strong Buy
Current$41.64 Low$38.00 Median$58.00 High$83.00 18 analysts
$38.00$83.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 1 bullish, 2 bearish, 2 mixed, 13 neutral · avg impact 3.4/10.
NEUTRAL8-K2/10
Alkermes appointed Anne C. Whitaker as an independent director, expanding the board from 10 to 11 me
Sep 16, 2026
NEUTRALCLUSTER2/10
Two senior Alkermes executives (EVP/CLO and EVP R&D/CMO) sold a combined $521K in open-market shares
Sep 3, 2026
BEARISHCLUSTER4/10
Three Alkermes insiders, including a director and two EVPs, sold a total of $2.78M in open-market sh
Aug 8, 2026
NEUTRALCLUSTER2/10
Two Alkermes executives (EVP CLO and EVP R&D/CMO) sold a combined $536K in open-market shares on Aug
Aug 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
short_volume
Short Volume: ALKS — 55.6% short (0.5M / 0.9M)
Short: 500,068 | Exempt: 0 | TRF Vol: 899,125 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: ALKS — 58.2% short (1.0M / 1.8M)
Short: 1,038,021 | Exempt: 20 | TRF Vol: 1,784,802 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: ALKS — 60.1% short (0.6M / 1.1M)
Short: 647,334 | Exempt: 0 | TRF Vol: 1,077,601 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: ALKS — 64.0% short (0.6M / 0.9M)
Short: 599,366 | Exempt: 93 | TRF Vol: 936,686 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: ALKS — 57.3% short (0.4M / 0.7M)
Short: 383,257 | Exempt: 246 | TRF Vol: 668,957 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.25 | $-0.04–$0.51 | -62.1% | +0.0% | 0↑ 1↓ | $0.5B | 4 |
| Next Q | $0.09 | $-0.55–$0.45 | -81.6% | +0.0% | 0↑ 1↓ | $0.5B | 4 |
| Current FY | $1.27 | $0.24–$2.25 | -39.2% | +0.0% | 1↑ 1↓ | $1.8B | 4 |
| Next FY | $1.81 | $0.71–$2.43 | 41.8% | -1.1% | 1↑ 1↓ | $1.9B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.247 | — |
| 7d ago | $0.247 | — |
| 30d ago | $0.247 | — |
| 60d ago | $0.415 | -0.168 |
| 90d ago | $0.361 | -0.114 |
Institutional ownership
Which big funds own ALKS (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $17.00 total value (1 shares) as of 2026-Q2. Top holders: HUNTINGTON.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 1 | $17.00 | 100.0% | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$5.5M — $0.00 bought, $5.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2,034 | $48.01 | $97.7K |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | EXERCISE | 5,000 | $24.59 | $123.0K |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | SELL | 9,000 | $46.99 | $422.9K |
| Aug 17, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | SELL | 6,912 | $49.19 | $340.0K |
| Aug 17, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | SELL | 664 | $49.65 | $33.0K |
| Aug 5, 2026 | Jackson Blair Curtis | President & CEO, Alkermes plc | AWARD | 93,229 | — | — |
| Aug 5, 2026 | Jackson Blair Curtis | President & CEO, Alkermes plc | AWARD | 124,305 | — | — |
| Aug 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2,034 | $48.58 | $98.8K |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | EXERCISE | 104 | $19.34 | $2.0K |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | EXERCISE | 4,896 | $24.59 | $120.4K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ALKS.
Shares short
15,156,775
Settlement Sep 15, 2026
Change vs prior
+3.0%
Semi-monthly cycle
Days to cover
10.7
At avg daily volume
Of shares outstanding
≈9.0%
Estimate — not % of float
All ALKS filing & press-release reports (18)
- 8-K reportSep 16, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 8, 2026
- CLUSTER reportAug 4, 2026
- CLUSTER reportAug 3, 2026
- 8-K reportJul 28, 2026
- 8-K reportJul 8, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 1, 2026
- 8-K reportMay 20, 2026
- DEFA14A reportMay 13, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMay 5, 2026
- CLUSTER reportMar 5, 2026
- 8-K reportFeb 25, 2026
- 8-K reportFeb 25, 2026